Navigation Links
Niusule Biotech Corp. to Commence Trading on the OTC Bulletin Board Under the Symbol 'NIUS'
Date:12/30/2008

CARSON CITY, Nev., Dec. 30 /PRNewswire-FirstCall/ -- Niusule Biotech Corp., a Nevada corporation formed on April 8, 2008, announced today that its shares of common stock will begin trading on the OTC Bulletin Board under the symbol "NIUS" on December 30th, 2008.

For a NIUS quote, visit: http://finance.yahoo.com/q?s=NIUS.OB

"Our main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp by manufacturing and selling biopharmaceutical and health food," said Qinghua Hu, Chairman of Niusule Biotech Corp. "We believe our public listing is a signal of Niusule Biotech Corp.'s maturity as a company. I would like to thank Niusule Biotech Corp.'s partners, employees and shareholders for their respective roles in contributing to our success."

In a meeting with employees, directors, and shareholders, Hu discussed Niusule Biotech Corp. goals and priorities as a publicly traded entity including:

    -- Build long-term value for shareholders by implementing our business
       plan;
    -- Seek cooperation and alliance with US companies manufacturing health
       food products for either distribution or production rights in China;
       and
    -- Commitment to being a leading player in China's health food industry
       and bioengineering industry.

"As we are in our initial stages of growth, we provide both small and institutional investors opportunities to invest in China's health food industry," said Hu. "The move to the OTC Bulletin Board positions the company to benefit from greater visibility and liquidity."

About Niusule Biotech Corp.

Founded in 2008, Niusule Biotech Corp.'s main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp. Niusule Biotech Corp. is trying to build a bridge between the USA and China in the health food industry and bioengineering industry by accessing the talent pools in both countries and by applying the mature technologies and high quality standards of the USA to its business model in China.

For more information about Niusule Biotech Corp., visit http://www.niusule.com.

This news release contains forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks described in the company's filings with the SEC.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
4. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
5. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
6. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
7. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
8. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
9. Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
10. Micromet Added to NASDAQ Biotechnology Index
11. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):